Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Inclusion Criteria: * Signed Informed Consent Form prior to any study-mandated procedure * Diagnosis of SLE made at least 6 months prior to Screening, by fulfilling at least 4 of the 11 criteria for SLE as defined by the American College of Rheumatology (ACR) criteria * A mSLEDAI-2K score ≥ 6 of at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). * Currently treated with stable doses of one or more of the following background medications: * NSAIDs * Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine) * Mycophenolate mofetil (≤ 2 g/day) * Mycophenolic acid (≤ 1440 mg/day) * Azathioprine (≤ 2 mg/kg/day) * Methotrexate (≤ 20 mg/week) * Corticosteroids (≤ 40 mg/day prednisone or equivalent) * Belimumab (≤10 mg/kg every 4 weeks intravenously, or 200 mg/week subcutaneously). * History or presence of positive autoantibodies measured by central laboratory defined as follows: (a) Positive antinuclear antibody (ANA) test measured by immunofluorescence assay (IFA) with titre ≥1:80; AND/OR (b) positive anti-double stranded deoxyribonucleic acid (anti-dsDNA) antibodies with titre ≥30 IU/mL * Women of childbearing potential: * Must have a negative serum pregnancy test at Screening * Must agree to undertake monthly urine pregnancy tests during the study * Must use highly effective methods of contraception from the screening visit until 6 mon…